WHO ICTRP trial
Clinical study of RD13-01 cell Injection in the treatment of patients with…
ChiCTR2000039243 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000039243 |
|---|---|
| Public title | Clinical study of RD13-01 cell Injection in the treatment of patients with recurrent or refractory T/NK line malignant hematologic tumor |
| Scientific title | Clinical study of RD13-01 cell Injection in the treatment of patients with recurrent or refractory T/NK line malignant hematologic tumor |
| Primary sponsor | JiangSu Province Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Treatment study |
| Phase | 1 |
| Countries | China |
| Conditions | Relapsed or refractory CD7 Positive T / NK hematological malignancies |
| Interventions | Low dose (ALL):The infusion of 2.0×10^6 CART+ cell/kg;Intermediate dose (ALL):The infusion of 5.0×10^6 CART+ cell/kg;High dose (ALL):The infusion of 1.0×10^7 CART+ cell/kg;Low dose (NHL):The infusion of 5.0×10^6 CART+ cell/kg;Intermediate… |
| Registration date | Oct 22, 2020 |
| Target size | Low dose (ALL):6;Intermediate dose (ALL):6;High dose (ALL):6;Low dose… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: